Vasculitis, characterized by inflammation of blood vessels, presents a complex and challenging spectrum of diseases. With diverse clinical manifestations and variable outcomes, treating vasculitis often demands a multifaceted approach. In recent years, biological therapies have emerged as promising interventions, offering targeted mechanisms to modulate the immune system and mitigate vascular inflammation. This article explores the current landscape of biological therapies in vasculitis, highlighting their efficacy, limitations, and the potential future directions shaping the field. Before delving into biological therapies, it's crucial to grasp the underlying pathology of vasculitis. This group of disorders involves inflammation of blood vessels, disrupting normal blood flow and potentially leading to tissue damage and organ dysfunction. Vasculitis encompasses a spectrum of diseases classified based on the size of the vessels affected, such as large vessel vasculitis (e.g., giant cell arteritis), medium vessel vasculitis (e.g., polyarteritis nodosa), and small vessel vasculitis (e.g., granulomatosis with polyangiitis). While the exact etiology remains elusive, dysregulation of the immune system is thought to play a central role in triggering and perpetuating vascular inflammation.
HTML PDFShare this article
Journal of Vasculitis received 83 citations as per Google Scholar report
